Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study
Authors not listed
Regeneron Pharmaceuticals · 2025
Abstract
This study will describe and estimate the incidence of Retinal Vasculitis (RV) events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea®, aflibercept 2mg) therapy in US clinical practice.
The main objective is to describe demographic and clinical characteristics of patients receiving aflibercept 2mg injections, to estimate the incidence of RV and RV plus Intraocular Inflammation (IOI) following aflibercept 2mg injections and to describe characteristics of RV cases.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-12 MST
Cite this
APA
Anonymous. (2025). Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study. <em>Regeneron Pharmaceuticals</em>. https://clinicaltrials.gov/study/NCT07105228
Vancouver
Anonymous. Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study. Regeneron Pharmaceuticals. 2025.
BibTeX
@misc{anon2025Incide,
title = {Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study},
author = {Anonymous},
journal = {Regeneron Pharmaceuticals},
year = {2025},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Regeneron Pharmaceuticals 2022
Open access · US-GOV
A US Real-World Evidence Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022
National University Hospital, Singapore 2013
Open access · US-GOV
Continuous Renal Replacement Therapy With Anticoagulation-free Regimen in Bleeding-risk Patients Using oXiris Membrane - CARROM Study
University of Sulaimani 2019
Open access · US-GOV
Senior House Officer of Trauma and Emergency Surgery
Bayer 2016
Open access · US-GOV
A retrospecTive and Prospective Non-Interventional Study to Assess the Clinical pracTice in Real Life for Patients With Wet AMD Refractory to raNibizumab and Switching to Aflibercept
IRCCS San Raffaele 2023
Open access · US-GOV
Multimodal Prehabilitation in Localized Pancreatic Cancer Patients Undergoing Surgery: a Randomized Controlled Trial
University of Aarhus 2003
Open access · US-GOV